This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schülin, T.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schülin, T.
Right arrow Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1999, p. 2873-2876, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Activities of the Oxazolidinones Linezolid and Eperezolid in Experimental Intra-Abdominal Abscess Due to Enterococcus faecalis or Vancomycin-Resistant Enterococcus faecium

T. Schülin, C. Thauvin-Eliopoulos, R. C. Moellering Jr., and G. M. Eliopoulos*

Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, and Harvard Medical School, Boston, Massachusetts 02115

Received 27 August 1998/Returned for modification 29 March 1999/Accepted 14 September 1999

The in vivo effectiveness of oxazolidinones eperezolid (U-100592) and linezolid (U-100766) against one strain each of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium was examined in a rat model of intra-abdominal abscess. MICs of both drugs were 2 µg/ml for each strain. At doses of 25 mg/kg of body weight twice daily intravenously or orally, linezolid produced small but statistically significant reductions in abscess bacterial density for E. faecalis. The reduction in viable cells observed would not likely be clinically relevant. Eperezolid was ineffective at this dose. At a dosage of 100 mg/kg/day, linezolid treatment led to an approximately 100-fold reduction in viable cells per gram of abscess. Against E. faecium infections, intravenous eperezolid and oral linezolid were effective, reducing densities approximately 2 log10 CFU/g. Both oxazolidinones demonstrated activity against enterococci in this model. However, results were modest with the dosing regimens employed.

* Corresponding author. Mailing address: Department of Medicine---West Campus, Beth Israel Deaconess Medical Center, One Deaconess Rd., Boston, MA 02215. Phone: (617) 632-8586. Fax: (617) 632-7442. E-mail: geliopou{at}caregroup.harvard.edu.

Antimicrobial Agents and Chemotherapy, December 1999, p. 2873-2876, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Miyazaki, S., Fujikawa, T., Kobayashi, I., Matsumoto, T., Tateda, K., Yamaguchi, K. (2002). The in vitro and in vivo antibacterial characterization of vancomycin and linezolid against vancomycin-susceptible and -resistant enterococci. J Antimicrob Chemother 50: 971-974 [Abstract] [Full Text]  
  • Andes, D., van Ogtrop, M. L., Peng, J., Craig, W. A. (2002). In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid). Antimicrob. Agents Chemother. 46: 3484-3489 [Abstract] [Full Text]  
  • Patel, R., Rouse, M. S., Piper, K. E., Steckelberg, J. M. (2001). Linezolid Therapy of Vancomycin-Resistant Enterococcus faecium Experimental Endocarditis. Antimicrob. Agents Chemother. 45: 621-623 [Abstract] [Full Text]  
  • Torres-Viera, C., Thauvin-Eliopoulos, C., Souli, M., DeGirolami, P., Farris, M. G., Wennersten, C. B., Sofia, R. D., Eliopoulos, G. M. (2000). Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis. Antimicrob. Agents Chemother. 44: 1720-1724 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»